Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 11th International Conference on Virology and Microbiology Vancouver, Canada.

Submit your Abstract
or e-mail to

events@conferenceseries.com

Scientific Program Day 1
Scientific Program Day 2

Day 1 :

Keynote Forum

Rongtuan Lin

Keynote: Manipulating the immune response to inhibit emerging virus infection

Time : 09:45-10:15

Conference Series Virology Congress 2018 International Conference Keynote Speaker Rongtuan Lin photo
Biography:

Rongtuan Lin has completed his PhD from Concordia University and Post-doctoral training at the Lady Davis Institute for Medical Research. He is an Associate Professor in the Department of Medicine, McGill University and a Senior Investigator at the Lady Davis Institute for Medical Research. He has authored more than 130 publications and has served on several grant review panels. His research focuses on the molecular understanding of the positive and negative regulation of antiviral immunity and to manipulate the innate immune response as a therapeutic strategy to control virus infection and cancer. His current interests include the use of small molecules that mimic viral RNA to inhibit Pathogenic virus infection.
 

Abstract:

Emerging or re-emerging virological threat represents a major public health problem. Pathogenic virus infection is controlled in large part by the host antiviral immune response. The innate immune response to virus infection plays a critical role in limiting virus multiplication and pathogenesis. Central to the innate antiviral response is the rapid induction of type I interferon (IFN) expression; IFN gene expression is tightly regulated by the recognition of extra- and intra-cellular signals, generated during primary infection. The viral genome or viral replicative intermediates containing 5’triphosphate (5’ppp) RNA binds to RIG-I and ultimately leads to the production of pro-inflammatory cytokines and anti-viral factors, as well as type I interferons (IFNs) that amplifies the antiviral immune response. Given that viral RNA-RIG-I interaction is the initial trigger of the innate and adaptive immune response, an attractive strategy for the development of an efficient and broad-spectrum antiviral therapy to inhibit virus replication involves the use of RIG-I agonist that mimic viral RNA to activate the host defense. Our recent work demonstrated that the RIG-I agonist molecules we have designed in-house have potent antiviral activity against a range of RNA and DNA viruses in-vitro and confer protection against Influenza H1N1 and HSV-1 virus infection in-vivo in the murine model. Our ongoing study demonstrated that RIG-I agonist also has potent antiviral activity against Ebola viruses in-vitro and in-vivo in the murine model. We seek to investigate the potential of 5’pppRNA as a prophylactic and therapeutic antiviral agent against Ebola virus and the mechanisms responsible for the observed protective effect.
 

 

Keynote Forum

Clayton A Dehn

Keynote: Early proof of concept with human viral challenge models in vaccine development

Time : 10:15-10:45

Conference Series Virology Congress 2018 International Conference Keynote Speaker Clayton A Dehn photo
Biography:

Clayton Dehn is a clinical research physiologist with particular expertise in Proof-of-Concept testing methods. He is a co-inventor of a process and substance for disturbing the inheritance pattern of ion-channelopathic disorders by selectively disabling genetically undesirable sperm cells. He is also the sole author of the first publication cautioning against the risk of SGLT-inhibition inducing ketoacidosis in insulinopenic populations. Clayton brings over 15 years of knowledge and international experience as a clinical research professional in the drug development industry.

Abstract:

The pharmaceutical industry is constantly searching for efficiencies for the development of new medicinal products. Viral vaccine development is no exception. The Human Viral Challenge Model (HVCM) is a widely accepted alternative to field studies. The standardized exposure of intentional viral inoculation of volunteers in a controlled clinical environment enriches the prevalence of infection. This also permits the study of the entire disease lifecycle from health to disease and recovery back to health. These methods reduce study population size requirements and the overall trial duration. The cumulative effect of these advantages is a risk and cost containing accelerated route to market for antiviral drugs, diagnostics and vaccines

Keynote Forum

Manja Marz

Keynote: Interface between bioinformatics and virology

Time : 11:00-11:30

Conference Series Virology Congress 2018 International Conference Keynote Speaker Manja Marz photo
Biography:

Since 07/2015, Manja Marz being full professorship for “High Throughput Sequencing Analysis” at Friedrich Schiller University Jena. Since 01/2015 group leader at Leibniz Institute for Age Research–Fritz Lipmann Institute and 04/2015 Founding and board member of FIFI (Fordervereinverein des Instituts fur Informatik) since 07/2013 Board member of ZAJ (Aging Research Center Jena) 04/2015 Founding member of MSCJ (Michael Stifel Zentrum Jena for Data-Driven and Simulation Science) 07/2013 Founding member of ZAJ (Aging Research Center Jena) 02/2012–06/2015 Junior-Professorship for “High Throughput Sequencing Analysis” at Friedrich Schiller University Jena 01/2010–01/2012 Group Leader of “RNA Bioinformatics” at Philipps-University Marburg. 

Abstract:

In the last years, we have witnessed both the emergence of new viral diseases (e.g. MERS, SARS) and the re-emergence of known diseases in new geographical areas (e.g. Zika, Dengue and Chikungunya). Virologists have traditionally concentrated on studying viruses that cause disease in humans, animals or plants. However, there has been estimated around 1031 viruses in the biosphere and only a minuscule fraction has been identified, yet. On the other hand, the power of new genome sequencing technologies, associated with new tools to handle “big data”, provide unprecedented opportunities to address fundamental questions in virology. We would like to emphasize that many of the common questions raised in virology require specific bioinformatics support and for the need to bring together the expertise of bioinformaticians and virologists. For this mission, the European Virus Bioinformatics Center (EVBC) was founded on 8th March 2017 in Jena, Germany. The EVBC has about 100 founding members from over 50 research institutions distributed across 13 European countries. The EVBC is intended to bring together virologists and bioinformaticians across Europe and provide a platform for the implementation of interdisciplinary collaborative projects at local and international scales. I will present first attempts to tackle with virus-specific programs open questions in (co-)phylogeny, high-throughput sequencing data analysis, virus detection, virus-host interaction and host barriers.
 

Keynote Forum

Francis O Eko

Keynote: A self-adjuvanting vaccine delivery platform with potential to eliminate the cold-chain hurdle

Time : 11:30-12:00

Conference Series Virology Congress 2018 International Conference Keynote Speaker Francis O Eko photo
Biography:

Francis O Eko is professor of Microbiology and Immunology at Morehouse School of Medicine, Atlanta (USA). His expertise is in design and development of self-adjuvanting, cold-chain free vaccines and vaccine adjuvants. Current research involves investigation of the mechanisms of Chlamydia infection- and vaccineinduced immunity and the effect of VCG-based adjuvants on immunity to mucosal and systemic vaccines. 

Abstract:

The requirement for vaccines to be kept sufficiently cold during transport makes vaccine distribution to some populations (where the vaccines are greatly needed) extremely challenging, if not impossible. We have designed a versatile vaccine delivery platform based on Vibrio cholerae ghosts (VCG) that eliminates the need for the expensive cold chain. Moreover, this platform is self-adjuvanting and capable of simultaneously delivering multiple vaccine antigens to the immune system. It also offers an attractive approach for developing combination vaccines, especially against diseases with epidemiological overlap. Here, we present data showing a VCG-based vaccine expressing the Chlamydia trachomatis porin B and polymorphic membrane protein D proteins protects against infertility in mice following mucosal immunization. Vaccine efficacy was assessed by evaluating the intensity and duration of genital chlamydial shedding following intravaginal challenge with live chlamydiae. Protection against upper genital tract pathology was determined by assessing infertility and tubal inflammation. We demonstrated that the elicited immune effectors reduced the length and intensity of genital chlamydial shedding as well as the incidence of tubal inflammation. Moreover, immunized mice were protected against Chlamydia-induced infertility. These results highlight the potential of the VCG platform for eliciting immunity in the female genital tract and preventing the sequelae of chlamydial infection such as infertility and upper genital tract inflammation.
 

Keynote Forum

Laura Hong

Keynote: Challenges and solutions for maintaining quality and potency of the product in vaccine development

Time : 12:00-12:30

Conference Series Virology Congress 2018 International Conference Keynote Speaker Laura Hong photo
Biography:

Laura Hong has more than 15 year’s extensive experience in biologics and vaccine development. She had been support for monoclonal antibody drug development in the area of CV, ID and oncology. In recent years, her major responsibilities have been leading a group in supporting vaccine process and formulation development and release, including stability of manufactured vaccine products. Sha has contributed in more than ten vaccine project development, including Gardasil and Gardasil 9 vaccine. 

Abstract:

Challenges and solutions for maintaining quality and potency of the product in vaccine development The quality of vaccines is increasingly guaranteed by the use of robust and reproducible production processes. FDA and other regulatory agencies generated recommendations and guidelines to ensure high quality levels. The present talk will be focus on the discussions of the following areas:
• Why need to assess the quality and the potency of vaccine product from early phase through the late phase vaccine development, even after licensure of the product
• Strategy thinking and planning in the assessment of the potency and safety of Human Vaccine: in vivo animal assay vs. in vitro assays.
• Cases studies to demonstrate the challenges and solutions to timely evaluate the quality and potency of vaccine products.
• Regulatory considerations of the potency evaluation of vaccine products
 

  • Vaccine Research & Development| Human Vaccines - Infectious & Non Infectious Diseases | Cancer and Immunotherapy Vaccine| Viral Infections | Immunology of Infections | Pediatric Infectious Diseases
Location: Red Cedar Ballroom C
Speaker

Chair

Bin Lu

Medimmune, USA

Session Introduction

Oreola Donini

Soligenix, Inc., USA

Title: Using monoclonal antibodies as immune correlates of protection: Thermostable ricin toxin vaccine development

Time : 12:30-12:55

Speaker
Biography:

Oreola Donini has more than 15 years of experience in drug discovery and preclinical development with start-up biotechnology companies and has been instrumental in leading early stage development of novel therapies into the clinic. She is a co-inventor of the Innate Defense Regulator technology. Her research has spanned drug discovery, preclinical development, manufacturing and clinical development in infectious disease, cancer and cancer supportive care. She is a Senior Vice-President and the Chief Scientific Officer with Soligenix. Dr. Donini received her PhD from Queen’s University in Kinston, Ontario, Canada and completed post-doctoral work at the University of California, San Francisco

Abstract:

Ricin is a highly toxic plant-derived toxin that causes a rapidly progressive respiratory syndrome when inhaled. Ricin toxin is easily derived from castor bean production and constitutes a serious biological threat agent. Soligenix is developing a ricin-toxin vaccine derived from the A-chain moiety of ricin (RiVax®), adjuvanted with aluminum and thermostabilized via lyophilization in conjunction with glassifying excipients. RiVax has demonstrated 100% protection in a rhesus macaque model of aerosolized ricin exposure and safety in two phase 1 clinical studies. Development of a ricin-toxin vaccine will require use of the “Animal Rule”. Use of the Animal Rule dictates the identification of immune correlates of protection that can be correlated between human studies and animal models. Recent studies have evaluated immunogenicity measures, including total antiricin IgG, neutralizing antibody levels, and epitope competition profiles as potential immune correlates of protection. Epitope competition assays have been specifically developed using neutralizing monoclonal antibodies with known recognition sites (epitopes) on ricin/RiVax. Studies in mice, non-human primates, and humans have suggested that the epitope competition profiles in particular are similar across species and, moreover, that threshold levels of epitope competition may be predictive of survival to subsequent ricin challenge. The stability of these same epitopes on the RiVax protein are also predictive of RiVax drug product potency. In aggregate, these results suggest that epitope recognition may be a powerful tool for vaccine development, particularly under the Animal Rule. This research was supported with funding from NIH/NIAID grant U01AI082210 and NIAID contract #HHSN272201400039C awarded to Soligenix, Inc.
 

Bryan Knight

Southern IML Pathology, Australia

Title: Changes to cervical screening in Australia: A strategy for a vaccinated population

Time : 13:55-14:20

Speaker
Biography:

Bryan Knight received medical training at the Godfrey Huggins School of Medicine, Zimbabwe. He trained in pathology at the University of Cape Town, South Africa and obtained his PhD at the same institution. He is an Associate of the College of American Pathologists, Fellow of the Royal College of Pathologists of Australasia, Fellow of the International Academy of Cytology and has a special interest in gynaecologic pathology and cytology. He has worked at UCT in South Africa, was Medical Director at the BC Cancer Agency in Vancouver Canada, and Director of Pathology at the Victorian Cytology Services in Melbourne, Australia.
 

Abstract:

The Australian National Cervical Cancer Screening Program commenced in 1982 and reduced the incidence of cervical cancer from 20 to 9 per 100,000 women by 2010. Since then the rate of reduction of cancers leveled off and remained relatively unchanged. In 2007, a National HPV (human papillomaviruses) Vaccine program for girls and young women using quadri-valent vaccine commenced and in 2009 became school-based and expanded to include boys. The nonavalent vaccine will be launched in 2018. Up-take of vaccination is above 80% and the incidence of HPV-related high-grade lesions has fallen in the vaccinated population. A smaller reduction in high-grade lesions in older women suggests a herd-immunity effect. With the reduced incidence of cervical lesions in the population, the low sensitivity of Papanicolaou smears will likely decline. In the HPV vaccine era, the need for a more sensitive and specific test with a high negative predictive value predicated on a change to HPV DNA testing. Numerous international studies show that HPV DNA testing with partial genotyping confers the most costeffective and effective means of population-based cervical screening. The Renewed HPV DNA Screening Program commenced in December 2017. A new National Cancer Screening Register will change the way women are invited to screening and are recalled for follow-up, aiming to reduce under-screening. Further, a new self-sample HPV DNA test to screen women who, for cultural or other reasons have not been screened, will enhance the efficacy of the program. A further reduction of the incidence of cervical cancer in Australia is anticipated.
 

Yang Jiaying

Southeast University, China

Title: Comparison of three sample size estimation methods for non-inferiority vaccine trials with multiple continuous co-primary endpoints

Time : 14:20- 14:45

Speaker
Biography:

Yang Jiaying has her expertise in research design and statistical analysis of vaccines and drug clinical trials. She has conducted in-depth research in the past few years in the randomization of subjects and the calculation of the sample size of tirals when there were multiple co-primary endpoints, and has been funded by the Fundamental Research Funds for the Central Universities and the Postgraduate Research Practice Innovation Program of Jiangsu Province.
 

Abstract:

Combination vaccines have been extensively used for decades and bring together the issue of intersection-union. To make up for the reduction in statistical power at the study level, researchers have to increase the study sample size. In view of the nature of immunogenicity variables, we use the geometric mean concentration of immune response after vaccination as immunologic endpoint and compare three sample size calculation methods: the “Inflation factors” method, the “Incrementing method” and the Bonferroni correction method when there are multiple continuous co-primary endpoints. The parameters are set according to the actual situation of combination vaccines and the simulation results were used as reference. The present study demonstrates that the “Incrementing method”, the Bonferroni corrected method and the “Inflation factors method” are all available when the effect size of each endpoint is comparable and there is no or weak correlation between each endpoint. When there is a valid difference of effect sizes among endpoints, the “Incrementing method” performs better.
 

Bin Lu

Medimmune, USA

Title: Molecular analysis of Respiratory Syncytial Virus (Rsv) F and G proteins during the 2015-2017 winter seasons in the USA and viral susceptibility to anti-Rsv monoclonal antibody (mAbs)

Time : 14:45-15:10

Speaker
Biography:

Bin Lu, PhD is currently Principle Scientist at Medimmune/AstraZeneca. He has 18 years of preclinical and clinical experience in the development of vaccines, monoclonal antibodies for infectious diseases. His experience includes Sr Direction and VP of R&D in a biotech startup and Co-PI for the CRADA programs with NIH on the evaluation of novel vaccines and antivirals. Dr Lu has authored over twenty peer-reviewed publications and is an inventor on several US patents related to development and production of vaccines for influenza and other serious viral respiratory diseases.
 

Abstract:

RSV is a leading cause of lower respiratory tract infections in infants. Palivizumab is the only approved agent for RSV prophylaxis limited to high-risk infants. MEDI8897, a potent anti-RSV F mAb with extended serum half-life, is under clinical investigation as a candidate for RSV passive vaccination in all infants entering their first RSV season. To monitor current RSV genotypes in circulation and natural polymorphisms in the F protein-binding regions of MEDI8897 and palivizumab, we determined G and F sequences of 1,228 RSV isolates collected in the OUTSMART surveillance program during 2015-16 (n=392) and 2016-17 (n=836) RSV seasons from 25 regional laboratories in the US and Puerto Rico. RSV A (62% in 201516 and 45% in 2016-17), RSV B (37% in 2015-16 and 54% in 2016-17), and RSVA/RSVB coinfection (1% in both seasons) were detected. All RSV A and RSV B isolate clustered into ON1 and BA genotypes, respectively. A few distinct substitution polymorphisms in the MEDI8897 binding region (AA62-69 and 196-212) of the F protein were identified in RSV A (residues 65, 68 or 206) and RSV B (residues 66, 209, 210 and double 201/209, 206/209) strains. The frequency of these variants was in the 0.2-2.1% range, except for the 206/209 variant detected at a frequency of ~19% in 2016-17. None of these F polymorphisms had an impact on viral susceptibility to MEDI8897 neutralization. One known palivizumab resistant variant at residue 272 of RSV A was observed in the palivizumab binding region (AA267-275). The ongoing OUTSMART study provides viral susceptibility monitoring for anti-RSV mAbs.
 

Li Luo

Southeast University, China

Title: The application of epidemic dynamics on the prediction and prevention of hand-foot-and-mouth disease (HFMD) induced by EV71 virus

Time : 15:10-15:35

Speaker
Biography:

Li Luo has her expertise in research design and statistical analysis of vaccines and drug clinical trials. She has conducted in-depth research in the past few years in the epidemic dynamics model and its application on the clinical trials, and the calculation of the sample size of cluster randomization trails.
 

Abstract:

Objective: The study aimed to develop an epidemic dynamics model for the transmission and prevention of hand-foot andmouth disease {HFMD}induced by EV71 virus.
 
Methods: A SEIR model for susceptible, exposed, infected and recovered HFMD patients was created based on research results and actual incidences of HFMD in China using mathematical and epidemic dynamical methods. Time-fitted curves determined by the relevant parameters were adopted to simulate the epidemic process and the effectiveness of the model with and without an intervention was evaluated.
 
Results: Comparison of the results of data fitting to the model for HFMD cases occurred in China from 2009 to 2015 with the actual incidence showed that the model fitted well to the maximum number of infected HFMD patients and that the simulated trend of epidemic process was identical to that of the actual situation. Implementation of intervention measures was demonstrated to effectively delay the onset of HFMD epidemic peaks and reduce the number of incidence during peak seasons. Finally, we make use of the parameter values of the year 2013 and 2014 to simulate and forecast the number of patients of 2015, and the predictive results inosculate well with the real-world situations.
 
Conclusion: The model created in this study is suitable for simulating the spread of HFMD in China and may be used to evaluate the effectiveness of relevant intervention and preventive measures.
 

Chien-Fu Hung

The Johns Hopkins University, USA

Title: Intramuscular vaccination targeting mucosal tumor draining lymph node enhances integrins-mediated Cd8+ T Cell infiltration to control mucosal tumor growth

Time : 16:00-16:25

Speaker
Biography:

Chien-Fu Hung is an associate professor of pathology and oncology and a professor of gynecology and obstetrics at the Johns Hopkins University School of Medicine. He is a member of the Johns Hopkins Kimmel Cancer Center. His research focuses on the prevention and treatment of cervical and ovarian cancers. His team is currently using an ascitogenic ovarian/peritoneal tumor model to investigate DNA vaccine strategies encoding ovarian tumor antigens identified by microarray and SAGE. He earned his Ph.D. in molecular biology from the University of Illinois. He completed a fellowship in pharmacology at the University of Pennsylvania and a fellowship in pathology at the Johns Hopkins University

Abstract:

Objective: Mucosal immunization is suggested to be crucial at for controlling tumors in the mucosal region; however, therapeutic DNA vaccination with electroporation in various mucosal sites has yet to become clinically adaptable. Since tumordraining lymph nodes (tdLNs) have been suggested as immune-educated sites that can be utilized to mount a potent antitumor immune response, we examined whether intramuscular DNA vaccination with electroporation at sites that target the mucosal tdLNs could elicit mucosal immune response to restrict tumor growth.

Methods: The efficacy and mechanism of intramuscular administration of a therapeutic DNA vaccine with electroporation at different sites was examined by lymphocyte analysis, tumor growth, mouse survival, as well as integrin expression, in mice bearing orthotopic HPV16 E6/E7+ syngeneic TC-1 tumors in various mucosal areas.

Results: While provoking comparable systemic CD8+ T cell responses, intramuscular hind leg vaccination generated stronger responses in cervicovaginal-draining LNs to control cervicovaginal tumors, whereas intramuscular front leg vaccination generated stronger responses in oral-draining LNs to control buccal tumors. Surgical removal of tdLNs abolished the antitumor effects of therapeutic vaccination. Mucosal-tdLN-targeted intramuscular vaccination induced the expression of mucosalhoming integrins LPAM-1 and CD49a by tumor-specific CD8+ T cells in the tdLNs. Inhibition of these integrins abolished the therapeutic effects of vaccination and the infiltration of tumor-specific CD8+ T cells into mucosal tumors.

Conclusions: Our findings demonstrate that tumor draining lymph nodetdLNs -targeted intramuscular immunization can effectively control mucosal tumors, which represents a readily adaptable strategy for treating mucosal cancers in humans. 

Claudia León-Sicairos

Autonomous University of Sinaloa, Mexico

Title: Iron responsive-like elements in the parasite Entamoeba histolytica

Time : 16:25-16:50

Speaker
Biography:

Claudia Leon-Sicairos has completed her PhD at the age of 29 years from Centro de Investigacion y Estudios Avanzados (CINVESTAV-IPN Mexico). She is the director of 15 theses. She has published more than 10 papers in reputed journal. She is National Basic Science Prize 2006 by the Glaxo SK Foundation.

Abstract:

Entamoeba histolytica is a human parasite capable of invading intestinal mucosa and spreading to other organs. It is a significant cause of morbidity and mortality in developing countries. E. histolytica uses diverse human proteins as sources of iron. Iron is an important factor for E. histolytica growth and virulence. In higher eukaryotes, the expression of ironregulated genes is mediated by RNA-protein interactions between Iron Responsive Elements (IREs) and cytoplasmic Iron Regulatory Proteins (IRPs). In this work, we show evidence of IREs in some amoebic virulence mRNAs that are capable of binding cytoplasmic proteins, supporting the presence of an IRE/IRP-like mechanism.
 

Gurfateh Singh

Rayat Bahra University, India

Title: Possible role of fibrates in attenuated cardio protective effect of ischemic preconditioning in hyperlipidemic condition

Time : 16:50-17:15

Speaker
Biography:

Teaching/Research Experiences: More than 13 Years. I have published more than 53 research/review papers in reputed International & National journals. Moreover I have attended more than 35 International/National conferences as Invited Speaker/LOC Member/Resource Person/Organising Secretary/Presenter etc. Supervised more than 55 PG & UG Research Scholars & going on.
 

 

Abstract:

Objective: The present study has been designed to investigate the beneficial role of Fenofibrate & Clofibrate in attenuated the cardioprotective effect of ischemic preconditioning (IPC) in hyperlipidemic rat heart. 
 
Materials & Methods: Experimental hyperlipidemia was produced by feeding high fat diet to rats for a period of 28 days. Isolated langendorff’s perfused normal and hyperlipidemic rat hearts were subjected to global ischemia for 30 min followed by reperfusion for 120 min. The myocardial infarct size was assessed macroscopically using triphenyltetrazolium chloride staining. Coronary effluent was analyzed for lactate dehydrogenase (LDH) and creatine kinase-MB release to assess the extent of cardiac injury. Moreover, the oxidative stress in heart was assessed by measuring thiobarbituric acid reactive substance, superoxide anion generation and reduced form of glutathione. 
 
Results: The ischemia-reperfusion (I/R) has been noted to induce oxidative stress by increasing TBARS, superoxide anion generation and decreasing reduced form of glutathione in normal and hyperlipidemic rat hearts. Moreover, I/R produced myocardial injury, which was assessed in terms of increase in myocardial infarct size, LDH and CK-MB release in coronary effluent and decrease in coronary flow rate in normal and hyperlipidemic rat heart. In addition, the hyperlipidemic rat heart showed enhanced I/R-induced myocardial injury with high degree of oxidative stress as compared with normal rat heart subjected to I/R. Four episodes of IPC (5 min each) afforded cardioprotection against I/R-induced myocardial injury in normal rat heart as assessed in terms of improvement in coronary flow rate and reduction in myocardial infarct size, LDH, CK-MB and oxidative stress. On the other hand, IPC mediated myocardial protection against I/R-injury was abolished in hyperlipidemic rat heart. However, Treatment with Fenofibrate (100 mg/kg/day, i.p.), Clofibrate (300mg/kg/day, i.p.) as a agonists of PPAR-α have not affected the cardioprotective effect of IPC in normal rat heart, but its treatment markedly restored the cardioprotective potentials of IPC in hyperlipidemic rat heart. 
 
Conclusion: It is noted that the high degree of oxidative stress produced in hyperlipidemic rat heart during reperfusion and consequent down regulation of PPAR-α may be responsible to abolish the cardioprotective potentials of IPC.
 

Katarzyna Sitarz

Jagiellonian University Medical College, Poland

Title: Disruption of Hpv-16 E1 and E2 regulatory genes as a prognostic factor in cervical cancer

Time : 17:15-17:40

Speaker
Biography:

Katarzyna Sitarz received BSc of Biotechnology in 2015 and MSc of Biochemistry in 2017 (both at the Jagiellonian University). Now she is MD student (from 2016) and PhD student (from 2017) at Jagiellonian University Medical College.
 

Abstract:

HPV-16 integration into the host chromosome is thought to be an event in cervical malignant transformation, as it may result in uncontrolled expression of viral E6/E7 oncoproteins after disruption or deletion of the viral E2 or E1 regulatory sequences. The purpose of the study was to determine the sites of E1 and E2 HPV16 sequence disruption in cervical cancer (Ca) and in low-grade squamous intraepithelial lesion (LSIL) as a control. The study was conducted in 26 women with HPV-16 infection (INNO-LiPA Genotyping, Belgium), with a diagnosis of Ca (n=11) and LSIL (n=15). Complete E1 and E2 sequences were amplified with 2 and 4 pairs of overlapping primer sets, respectively. The polymorphisms of E1 and E2 were identified by sequencing. The results were compared with the prototype sequence (Gen-Bank no. K02718). In the LSIL group, the deletion of the E1 or E2 sequence of HPV16 occurred at a similar rate (13%), while in 46% of the patients the disruption was detected in both genes. In 4 cases no damage was shown. In cervical cancer, interruption of the E2 sequence occurred in all samples but in 3 together within the E1 sequence. The most frequently occurring damage was the E2 hinge region. Preliminary studies suggest that the site of disruption within the E2 sequence m